Explore

Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn to Lead Clinical and Regulatory Strategy

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn to Lead Clinical and Regulatory Strategy

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn to Lead Clinical and Regulatory Strategy
Trendline Trendline
Parabilis Medicines Files for IPO to Fund Cancer Drug Trials

Parabilis Medicines Files for IPO to Fund Cancer Drug Trials

Parabilis Medicines Files for IPO to Fund Cancer Drug Trials
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promising Safety Profile
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth
Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development

Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development

Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development
Trendline Trendline
Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment

Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment

Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth